Small molecule · Modulator of sphingosine 1-phosphate receptor 1 (S1PR1), sphingosine 1-phosphate receptor 4 (S1PR4) and sphingosine 1-phosphate receptor 5 (S1PR5) · developed by Pfizer
Etrasimod is an oral sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1, 4 and 5. It partially and reversibly blocks lymphocyte egress from lymphoid organs, reducing circulating lymphocytes, and is studied in ulcerative colitis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 18, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03950232 | Phase 3 | Ulcerative Colitis | Active not recruiting | PFE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ulcerative Colitis
Updated Nov 8, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →